Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation.
Best Pract Res Clin Gastroenterol
; 31(2): 187-198, 2017 Apr.
Article
in En
| MEDLINE
| ID: mdl-28624107
ABSTRACT
Liver transplantation is a well-accepted treatment for decompensated chronic liver disease due to primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) and auto-immune hepatitis (AIH). Survival after liver transplantation is generally good with 1 and 5-year survival rates around 90% and 70-85%. After transplantation, however, these diseases recur in 8.6-27% (rPSC), 10.9-42.3% (rPBC) and 7-42% (rAIH), and this poses significant challenges in terms of management and graft outcome in these patients. In this review we discuss the incidence, clinical presentation, challenges in diagnosis, reported risk factors and impact on post-transplant outcomes of recurrence of PSC, PBC and AIH after liver transplantation. We also discuss some of the limitations of current investigations and formulate idea's for future research objectives.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cholangitis, Sclerosing
/
Liver Transplantation
/
Hepatitis, Autoimmune
/
Liver Cirrhosis, Biliary
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Best Pract Res Clin Gastroenterol
Journal subject:
GASTROENTEROLOGIA
Year:
2017
Document type:
Article